Basilea Announces Submission of a New Drug Application to the US Food and Drug Administration for its Antibiotic Ceftobiprole

Allschwil, Switzerland, August 04, 2023 -- Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news